CN115698077A - 结合bcma的单可变结构域及抗原结合分子 - Google Patents

结合bcma的单可变结构域及抗原结合分子 Download PDF

Info

Publication number
CN115698077A
CN115698077A CN202180041402.4A CN202180041402A CN115698077A CN 115698077 A CN115698077 A CN 115698077A CN 202180041402 A CN202180041402 A CN 202180041402A CN 115698077 A CN115698077 A CN 115698077A
Authority
CN
China
Prior art keywords
seq
amino acid
single variable
acid sequence
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180041402.4A
Other languages
English (en)
Inventor
甄子朋
谢美娟
杜秀贞
马毅敏
张兵
徐同杰
张喜全
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN115698077A publication Critical patent/CN115698077A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

提供了一种结合BCMA的免疫球蛋白单可变结构域及抗原结合分子，具体地包括免疫球蛋白单可变结构域及抗原结合分子、编码它们的核酸、包含该核酸的载体、包含该载体的细胞、包含它们的药物组合物，还提供了其治疗用途。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202180041402.4A 2020-08-20 2021-08-16 结合bcma的单可变结构域及抗原结合分子 Pending CN115698077A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010842501 2020-08-20
CN202010842501X 2020-08-20
PCT/CN2021/112758 WO2022037528A1 (zh) 2020-08-20 2021-08-16 结合bcma的单可变结构域及抗原结合分子

Publications (1)

Publication Number Publication Date
CN115698077A true CN115698077A (zh) 2023-02-03

Family

ID=80323414

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180041402.4A Pending CN115698077A (zh) 2020-08-20 2021-08-16 结合bcma的单可变结构域及抗原结合分子

Country Status (6)

Country Link
US (1) US20230265181A1 (zh)
EP (1) EP4201960A1 (zh)
JP (1) JP2023539453A (zh)
KR (1) KR20230045095A (zh)
CN (1) CN115698077A (zh)
WO (1) WO2022037528A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4324853A1 (en) * 2021-04-15 2024-02-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Multi-specific antibody targeting bcma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6061469B2 (ja) * 2009-03-10 2017-01-25 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗ｂｃｍａ抗体
UA112434C2 (uk) * 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
BR112019026907A2 (pt) * 2017-06-20 2020-06-30 Teneobio, Inc. Anticorpos apenas de cadeia pesadaanti-bcma, polinucleotídeo, vetor, célula,composição farmacêutica, seus usos e método paraproduzir os mesmos
CN111601825B (zh) * 2018-02-01 2022-11-29 信达生物制药(苏州)有限公司 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用

Also Published As

Publication number Publication date
JP2023539453A (ja) 2023-09-14
EP4201960A1 (en) 2023-06-28
WO2022037528A1 (zh) 2022-02-24
US20230265181A1 (en) 2023-08-24
KR20230045095A (ko) 2023-04-04

Similar Documents

Publication Publication Date Title
WO2018161872A1 (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
CN112625136A (zh) 针对冠状病毒具有中和活性的双特异性抗体及其用途
CN112513090B (zh) 结合人il-4r的抗体、其抗原结合片段及其医药用途
WO2021213435A1 (zh) 一种靶向人程序性死亡配体1(pd-l1)的单可变域抗体及其衍生物
US20120316085A1 (en) Antibody humanization by framework assembly
CN113412281A (zh) Btn3a结合蛋白及其用途
WO2022127889A1 (zh) Her2抗体及其应用
WO2021197401A1 (zh) 结合cd47的抗原结合多肽及用途
US20200369774A1 (en) Il-6r antibody and antigen binding fragment thereof and medical use
WO2022037528A1 (zh) 结合bcma的单可变结构域及抗原结合分子
CN115109156A (zh) 一种靶向bcma的纳米抗体及其应用
CN113880951A (zh) 凝血因子xi(fxi)结合蛋白
CN110343181B (zh) 针对凝血因子ix(fix)的单域抗体
WO2022037527A1 (zh) 结合bcma的单可变结构域及抗原结合分子
KR20230035079A (ko) 응고인자 xi(fxi) 결합 단백질
CN115521377A (zh) 人表皮生长因子受体结合分子及其应用
CN113880949A (zh) 凝血因子xi(fxi)结合蛋白
CN113880950A (zh) 凝血因子xi(fxi)结合蛋白
CN110407942B (zh) 针对kn044的单域抗体
WO2023078393A1 (zh) 抗c-Met抗体及其应用
WO2023078391A1 (zh) 结合c-Met的抗体及其应用
WO2024012434A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2024017326A1 (zh) 抗gprc5d纳米抗体及其应用
WO2023092327A1 (en) Vegf-binding protein and use thereof
TWI840399B (zh) 結合人il-4r的抗體、其抗原結合片段及其醫藥用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination